Bristol Myers Squibb stock holds near USD 63 as investors look to October 29 results

Published on 09/20/2026 at 11:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock closed at USD 63.06 on the New York Stock Exchange on September 18, 2026, about 8 percent below its 52-week high. Analysts see 2026 EPS near USD 6.9, keeping valuation in focus ahead of the October 29, 2026 Q3 report.

BMY, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb stock (ISIN US1101221083) ended at USD 63.06 on the New York Stock Exchange on September 18, 2026, leaving the large cap biopharmaceutical name trading close to recent levels as investors position for the next quarterly update. As of September 18, 2026, the closing price put the shares roughly 8 percent below a 52-week high around USD 68.64, keeping valuation and earnings expectations in focus ahead of the upcoming results.

Upcoming Q3 2026 earnings date sets the tone

According to Ad-hoc-news on September 18, 2026, Bristol Myers Squibb will report financial results for the third quarter of 2026 on October 29, 2026, with the earnings call scheduled for 8:00 a.m. ET. The upcoming quarter will be measured against a 2025 base year in which revenue reached about USD 48.2 billion and net income was nearly USD 7.1 billion, as highlighted by Ad-hoc-news. For investors, these numbers frame the growth and profitability expectations that will be tested when the new quarterly data arrive.

Forward-looking estimates have moved up in recent weeks. As Ad-hoc-news reported on September 18, 2026, Zacks lifted its 2026 EPS estimate for Bristol Myers Squibb to USD 6.91 from USD 6.34 over the past 60 days and its 2027 EPS estimate to USD 6.46 from USD 6.12. That increase of USD 0.57 per share in the 2026 forecast, or about 9 percent, points to rising confidence in the earnings trajectory, and it is a key comparison point when the company issues fresh guidance and numbers.

Valuation, EPS and revenue context

Price data underline that Bristol Myers Squibb remains valued as a defensive large cap but at a discount to some peers. Per a profile of the company on Forbes as of September 18, 2026, the stock closed at USD 63.06 on the New York Stock Exchange with the session high identical to the close and the low at USD 62.19, on volume of 36,576,219 shares. Using the USD 63.06 reference price and the approximately USD 48.2 billion revenue reported for fiscal year 2025, investors can derive a price to sales ratio around 2.6, which sits below many faster-growing biopharmaceutical peers and underpins the value case.

The same Forbes overview shows trailing twelve-month revenue of USD 49.19 billion and diluted EPS over the last twelve months of USD 4.54, with year-over-year diluted EPS growth of 82.74 percent. While trailing figures are backward-looking, they confirm that earnings have accelerated sharply versus the prior period, and they provide a benchmark against which the projected 2026 EPS of USD 6.91 can be measured. If Bristol Myers Squibb delivers on that 2026 forecast, EPS would rise by roughly 52 percent from the trailing USD 4.54 baseline, underscoring how much the company’s profit profile is set to improve if guidance is met.

Valuation multiples also look restrained in a wider sector context. According to Ad-hoc-news on September 18, 2026, Mitrade stated that Bristol Myers Squibb traded at a forward price to earnings ratio of 9.2 times, compared with AbbVie at 18.5 times. That means Bristol Myers Squibb’s forward multiple is about half the level of AbbVie’s, a quantified gap that investors interpret either as a valuation opportunity or as a discount reflecting pipeline, patent or policy risk.

Policy backdrop and product exposure

Beyond valuation metrics, regulatory and policy developments form part of the investment backdrop. Bristol Myers Squibb co-markets the anticoagulant Eliquis, a product directly affected by US drug pricing initiatives. By September 18, 2026, the White House stated that recent drug arrangements had delivered one million free Eliquis prescriptions to Medicaid and brought 26 manufacturers into the program, covering about 89 percent of the branded drug market, with projected savings to Medicaid of USD 64.3 billion over the next decade, as reported by NewsBreak. For Bristol Myers Squibb, broader access can support prescription volumes but also compress realized pricing, so the net effect on revenue and margins from Eliquis will be an important data point in upcoming reports.

Investors will watch closely how Bristol Myers Squibb balances volume growth and price pressure across its portfolio. In fiscal year 2025, the company generated about USD 48.2 billion of revenue and nearly USD 7.1 billion of net income according to Ad-hoc-news. That implied a net margin in the mid-teens, and any shift up or down in that margin in the 2026 quarters will indicate whether cost discipline and product mix can offset pricing headwinds from initiatives such as the Eliquis Medicaid deal.

Stock level, market cap and trading context

From a pure market perspective, the latest closing price and range figures help define the risk and return profile. Per Ad-hoc-news on September 18, 2026, Bristol Myers Squibb closed at USD 62.84 on the New York Stock Exchange on September 17, 2026, with a market capitalization around USD 129.46 billion and a 52-week high of USD 68.64. Relative to that high, the USD 62.84 level left the stock about 8.4 percent below its peak, a quantified distance that gives investors room for potential upside if fundamentals and sentiment improve while also illustrating that the shares are not trading at depressed crisis lows.

Daily trading volumes underscore the stock’s liquidity. The Forbes data show that on September 18, 2026, about 36,576,219 Bristol Myers Squibb shares changed hands, with the day’s range between USD 62.19 and USD 63.06. High liquidity reduces transaction costs and allows institutional investors to adjust positions around events such as the October 29, 2026 earnings release without materially impacting the price, which is part of the appeal of a large-cap pharmaceutical stock.

Stock price as of the latest close

As of September 18, 2026, Bristol Myers Squibb stock closed at USD 63.06 on the New York Stock Exchange, in United States dollars, after trading between USD 62.19 and USD 63.06 during the session. That closing level, combined with a market capitalization reported around USD 129.46 billion as of September 17, 2026, positions the company firmly among the largest global biopharmaceutical issuers and sets the stage for how the market will react to the Q3 2026 report on October 29, 2026.